Achieve life sciences announces expansion of cytisinicline clinical operations team and granting of inducement awards

Seattle, wa and vancouver, bc / accesswire / august 13, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the company has expanded its clinical operations team with the hiring of a director of clinical operations, a senior manager of clinical trials, and a senior director of biometrics. "we are excited to welcome our new clinical team members to achieve and look forward to their contributions to the cytisinicline development program, including their efforts to support our fully enrolled phase 3 orca-2 trial in combustible cigarette cessation and the planned phase 2 orca-v1 trial in nicotine e-cigarette cessation," commented dr. cindy jacobs, achieve's president and chief medical officer.
ACHV Ratings Summary
ACHV Quant Ranking